Atea Pharmaceuticals Inc is a biotechnology business based in the US. Atea Pharmaceuticals Inc shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Atea Pharmaceuticals Inc employs 56 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Atea Pharmaceuticals Inc
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AVIR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Atea Pharmaceuticals Inc stock price (NASDAQ: AVIR)Use our graph to track the performance of AVIR stocks over time.
Atea Pharmaceuticals Inc shares at a glance
|Latest market close||$7.30|
|52-week range||$7.24 - $94.17|
|50-day moving average||$9.11|
|200-day moving average||$24.46|
|Wall St. target price||$9.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.31|
Buy Atea Pharmaceuticals Inc shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Atea Pharmaceuticals Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Atea Pharmaceuticals Inc price performance over time
|1 week (2022-01-10)||-4.95%|
|1 month (2021-12-17)||-14.62%|
|3 months (2021-10-15)||-81.42%|
|6 months (2021-07-16)||-68.12%|
|1 year (2021-01-15)||-86.34%|
|2 years (2020-01-13)||N/A|
|3 years (2019-01-13)||N/A|
|5 years (2017-01-13)||N/A|
Is Atea Pharmaceuticals Inc stock undervalued or overvalued?
Valuing Atea Pharmaceuticals Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atea Pharmaceuticals Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atea Pharmaceuticals Inc's P/E ratio
Atea Pharmaceuticals Inc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Atea Pharmaceuticals Inc shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, Atea Pharmaceuticals Inc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Atea Pharmaceuticals Inc's EBITDA
Atea Pharmaceuticals Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $37.9 million.
The EBITDA is a measure of a Atea Pharmaceuticals Inc's overall financial performance and is widely used to measure a its profitability.
To put Atea Pharmaceuticals Inc's EBITDA into context you can compare it against that of similar companies.
Atea Pharmaceuticals Inc financials
|Revenue TTM||$207.8 million|
|Operating margin TTM||18.21%|
|Gross profit TTM||$10.6 million|
|Return on assets TTM||4.96%|
|Return on equity TTM||7.26%|
|Market capitalisation||$655.7 million|
TTM: trailing 12 months
Atea Pharmaceuticals Inc share dividends
We're not expecting Atea Pharmaceuticals Inc to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (3.96% forward annual dividend yield)
- GlaxoSmithKline (GSK.US) (4.83% forward annual dividend yield)
- Novartis (NVS.US) (3.53% forward annual dividend yield)
Atea Pharmaceuticals Inc overview
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States.
Atea Pharmaceuticals Inc in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation
Atea Pharmaceuticals (ATEA) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
Frequently asked questionsWhat percentage of Atea Pharmaceuticals Inc is owned by insiders or institutions?
Currently 18.427% of Atea Pharmaceuticals Inc shares are held by insiders and 75.971% by institutions. How many people work for Atea Pharmaceuticals Inc?
Latest data suggests 56 work at Atea Pharmaceuticals Inc. When does the fiscal year end for Atea Pharmaceuticals Inc?
Atea Pharmaceuticals Inc's fiscal year ends in December. Where is Atea Pharmaceuticals Inc based?
Atea Pharmaceuticals Inc's address is: 125 Summer Street, Boston, MA, United States, 02110 What is Atea Pharmaceuticals Inc's ISIN number?
Atea Pharmaceuticals Inc's international securities identification number is: US04683R1068
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
Ask an Expert